Title: Characterization of copy number alterations in Pakistani patients with colorectal cancer

Authors: Clayton T. Marcinak1, Bradon R. McDonald1, Hina Zubairi2, Sabeehuddin Siddique3, Michelle D. Stephens1, Munira Moosajee4, Rashida Ahmed3, Syed Nabeel Zafar1, Muhammed Murtaza1*, Kulsoom Ghias2*

1Department of Surgery and Center for Human Genomics and Precision Medicine, University of Wisconsin–Madison, Madison WI 53705, USA
2Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan
3Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan
4Department of Oncology, Aga Khan University, Karachi, Pakistan
5Current affiliation: Al Salam Al Assima Hospital, Kuwait City, Kuwait
*equally contributing, co-corresponding authors

Research support:

C. Marcinak is supported by grant 5 T32 HG002760 from the National Human Genome Research Institute. S. N. Zafar is supported by grant 3 P30 CA014520-48S4 from the National Cancer Institute Early-Stage Surgeon Scientist Program. M. Murtaza is supported by grants 5 R01 CA223481 and 5 U01 CA243078 from the National Cancer Institute of the National Institutes of Health (NIH). Data generation in this study was supported by the Ebrahim Endowment Fund.

Corresponding authors' contact information:

Kulsoom Ghias, PhD
Associate Professor and Chair
The Feerasta Family Endowed Chair
Department of Biological and Biomedical Sciences
The Aga Khan University
Stadium Road, P.O. Box 3500
Karachi 74800, Pakistan
Tel.: +92 3486 4464
Email: kulsoom.ghias@aku.edu

Muhammed Murtaza, MBBS, PhD
Associate Professor
Division of Surgical Oncology
Department of Surgery
University of Wisconsin–Madison
1111 Highland Avenue
Madison, WI 53705, USA
Tel.: +1 (608) 890-4154
Email: murtaza@surgery.wisc.edu

Running Head: Colorectal cancer genomics in Pakistan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Purpose:
Incidence and mortality rates of colorectal cancer (CRC) in South Asia are expected to rise by 70% between 2020 and 2040. Despite recent advances in the understanding of molecular alterations in CRC, the representation of South Asians in published genomic datasets is very limited. To address this gap, we performed a pilot study based on a transnational collaboration between academic centers in the US and Pakistan to characterize copy number alterations in a Pakistani cohort with CRC.

Methods:
We obtained archived formalin-fixed paraffin-embedded (FFPE) tissue samples from 43 CRC patients treated at Aga Khan University (AKU) Hospital. DNA was extracted and evaluated for quality at AKU, and whole genome sequencing library preparation and shallow whole genome sequencing was performed at University of Wisconsin–Madison. Sequencing data was aligned to the human genome, and we used ichorCNA and GISTIC2 to determine relative copy number alterations.

Results:
After removing 13 samples with insufficient DNA quality or quantity, tumor sequencing data was analyzed from 30 patients. The cohort consisted of 19 (63.3%) males with a mean age of 50.1 years and standard deviation (SD) of 17.8 years. Twenty-one (70.0%) patients had tumor stage T3 or T4, and 15 (50.0%) had tumors of the colon. A mean of 265 ng (SD, 29 ng) of DNA was extracted from each FFPE tumor sample, and each sample was sequenced to a mean depth of 0.22× (0.21×). Analysis of copy number alterations revealed recurrent gains in regions 8q and 13q, as well as losses in region 8p.

Conclusions:
This transnational pilot study helped identify the challenges related to FFPE sample quality that can impede similar efforts in the future. Our results revealed similarities in the most common copy number alterations in CRC identified in native Pakistani patients and published datasets.
**Introduction**

Colorectal cancer (CRC) is the third most common cancer worldwide and is responsible for nearly two million cases and one million deaths each year.\(^1\) In Pakistan, CRC ranked in the top ten cancers in terms of both incidence and mortality in the year 2020.\(^2\) Furthermore, low- and middle-income countries (LMICs) are expected to demonstrate a steep increase in cancer incidence and mortality due to changes in diet and environmental exposures.\(^3\)

Since the founding of The Cancer Genome Atlas (TCGA) project in 2005, considerable investment has been made to characterize the molecular alterations underlying many cancer types, including CRC.\(^4\) As a result, investigators and clinicians alike have gained valuable insight into disease-causing and potentially targetable genomic changes in CRC, including mutations in \textit{APC} and \textit{KRAS} and copy number alterations in \textit{MYC} and \textit{ERBB2}.\(^4,5\) However, TCGA draws overwhelmingly from patients of European descent. A 2020 analysis by Carrot-Zhang \textit{et al.} examined 10,678 individuals from TCGA, of whom over 80% were of European descent.\(^6\) While South Asians constitute approximately 25% of the world's population, only 0.25% of participants in the TCGA—27 patients total—were of South Asian descent. Genomic characterization data of cancer in South Asian populations is very limited, and whether these tumors have similar somatic genomic alterations compared to those described in TCGA is unknown. This knowledge gap has multiple downstream implications, including the inability to design clinical trials guided by actionable cancer mutations, the inability for clinicians to evaluate and apply new advances in therapeutics and diagnostics for South Asian patients, and missed opportunities to further understand carcinogenesis in distinct genetic and environmental backgrounds.

There are several barriers that drive under-representation of patients from LMICs in global efforts to characterize cancer genomes. These barriers include limited research funding, minimal access to expensive cutting-edge genomic technology, fewer personnel with the required skillset for genomic analysis, and a lack of genomics-friendly sample processing workflows. Recent advances in sequencing technologies have significantly lowered the upfront investment and recurring costs for sequencing data generation, yet there is still a significant need to improve local computational and technical know-how in LMICs. One way to address this knowledge gap is to establish transnational collaborations that leverage high-throughput genomics technologies.
widely available in academic centers across the United States to characterize tumor and blood samples from patients with cancer living in LMICs. These collaborations can create opportunities for capacity building, skills training in genomics and precision medicine, and identifying promising avenues for further research.

Here, we report results from one such pilot collaboration, in which we harness efficient and scalable shallow whole genome sequencing (WGS) to broaden our limited understanding of genomic changes driving colorectal cancer carcinogenesis in the Pakistani population.

**Methods**

**Study design and informed consent**

This study was performed following review and approval by the Ethical Review Committee at Aga Khan University (Reference #: 0442; originally 4665-BBS-ERC-17) and Pakistan’s National Bioethics Committee (Reference #: 4-87/NBC-251). We identified available formalin-fixed paraffin-embedded (FFPE) tumor blocks from surgical resections performed for CRC between 2009 and 2014 in the archives of the Department of Pathology and Laboratory Medicine at Aga Khan University Hospital (AKUH) in Karachi, Pakistan. The histopathology service at AKUH receives tissue samples from surgical resections performed at the hospital, as well as from referring hospitals within the country. To include these samples in the current study, we contacted the patients or their next of kin to obtain informed consent for use of samples.

**DNA extraction**

We stained mounted tissue sections using hematoxylin and eosin (H&E) to identify tumor regions within each FFPE tissue block. Tumor cellularity of patient material in each block was determined by histopathologists. We isolated DNA from identified tumor sections of each block into 20 µL of suspension buffer using the QIAmp DNA FFPE Tissue Kit as per manufacturer’s protocol (QIAGEN, Hilden, Germany). Quality and quantity of isolated DNA was determined using NanoDrop spectrophotometry and Qubit fluorometry (both from ThermoFisher Scientific, Waltham, MA, USA). After extraction and quality assessment at AKUH, DNA samples were shipped to the University of Wisconsin–Madison (UW–Madison) for library preparation and sequencing.
Whole genome sequencing
We sheared the DNA by sonication using the Bioruptor Pico (Diagenode Inc., Denville, NJ, USA) as needed to achieve a target template size of 300 bp. Shearing settings varied from 0 to 6 cycles of one minute duration (30 seconds on, 30 seconds off), depending on initial assessment of fragment size distribution evaluated using the 4200 TapeStation System (Agilent Technologies, Santa Clara, CA, USA). We prepared WGS libraries from the extracted DNA using the Takara ThruPLEX HV kit (Takara Bio USA, San Jose, CA, USA), as per manufacturer’s protocol. Sequencing libraries were assessed for quality and concentration using the High Sensitivity D1000 Assay on 4200 TapeStation. We generated sequencing data using the NextSeq 1000 System (Illumina Inc., San Diego, CA, USA), generating 100 bp paired-end reads. After on-board FASTQ conversion and sample demultiplexing, sequencing data were aligned to human genome build hg19 using BWA-MEM. We marked duplicate reads and calculated alignment statistics using SAMtools.

Analysis of copy number aberrations
We used ichorCNA version 0.3.2 to perform copy number analysis of all autosomal chromosomes with 500kb windows. ichorCNA evaluates the relative ratio in each 500kb bin between a test sample and a panel of normal DNA samples. Based on changes in these ratios across the genome, these bins are grouped in segments and annotated for copy number aberrations. Prior to ichorCNA analysis, we calculated read depth at each bin using BEDTools. To establish baseline variation in read depth for ichorCNA using normal DNA samples, we used shallow WGS data generated from DNA from a panel of 16 adjacent normal FFPE tissue. These adjacent normal samples were also obtained from the histopathology archive at AKUH and evaluated to be tumor negative by histopathology. Normalized log2 depths for each bin calculated by ichorCNA were used as the input for Genomic Identification of Significant Targets in Cancer, version 2.0 (GISTIC2), to evaluate whether any observed copy number alterations were statistically enriched in this cohort.

Statistical analysis
Descriptive statistics were performed using frequency for categorical variables and mean with standard deviation (SD) for continuous variables. Tumor cellularity is presented as median and interquartile range (IQR). All analyses were performed using Julia, version 1.7, and R, version 4.2.2 (R Project for Statistical Computing, Vienna, Austria; www.r-project.org).

Results

Cohort characteristics
Tumor blocks from 43 patients underwent DNA extraction and quality assessment. Of these, 13 samples were deemed ineligible for analysis due to either extensive DNA degradation or insufficient DNA quantity. The final cohort consisted of 30 patients: 19 (63.3%) males and 11 (36.7%) females, with an average age of 50.1 years (SD, 17.8 years) at the time of diagnosis. Age of diagnosis was unknown for two patients (6.7%). The majority of the cohort (21 patients, 70.0%) had T3 or T4 tumors at the time of histopathologic examination, while 16 patients (53.3%) had node-negative disease. Fifteen patients (50.0%) had a tumor of the colon, while 12 (40.0%) had more distal tumors of the rectosigmoid junction or rectum. The complete clinical characteristics of the cohort are shown in Table 1.

Sample and sequencing metrics
An average of 265 ng (SD, 290 ng) was extracted from each FFPE tumor sample. A mean of 5.9 ng (SD, 7.1 ng) of DNA was used as input for whole genome library preparation. Shallow WGS generated an average of 27.9 million reads (SD, 24.8 million), with a mean unique depth of 0.22× (SD, 0.21×). Based on ichorCNA results, median tumor cellularity was 13.6% (IQR, 0.3% to 26.9%).

Copy number aberrations
Two representative ichorCNA plots showing the copy number alterations across the genome are shown in Figure 1A. Patient CRC-06 is a male in the fifth decade of life with a well-differentiated, 7.5 cm tumor of the colon with concomitant nodal disease. Patient CRC-25 is a male in the second decade of life with poorly differentiated rectal adenocarcinoma in situ (Tis). Both tumors exhibit copy number gains in chromosomes 8 and 19, as well as copy number losses...
in chromosome 18. The genome-wide copy number alteration profiles of tumors for which sample cellularity is estimated to be $\geq 3\%$ by ichorCNA are shown in Figure 1B ($n = 25$).

Using GISTIC2 across the 25 samples with tumor cellularity $\geq 3\%$, we identified two genomic regions with copy number gains exceeding the threshold for a statistically significant recurrent alteration: 8q24.22 and 13q12.3 (Figure 2). Meanwhile, region 8p21.3 demonstrated copy number loss exceeding similar cohort-wide thresholds for recurrence (Figure 2).

**Discussion**

In this new collaboration between academic institutions in Pakistan and the United States, we were able to successfully analyze copy number alterations in a cohort of 30 Pakistani patients with CRC using shallow WGS. We found recurrent copy number alterations in three genomic regions: copy number gains in 8q and 12q, and copy number loss in 8p. Specifically, 8q24.22 lies adjacent to the coding region for the *MYC* oncogene, overexpression of which is highly implicated in the pathogenesis of CRC through the *Wnt* signaling pathway.\textsuperscript{14,15} Region 8q24 is also notable as the location of *PVT1* and several other long non-coding RNA sequences implicated in many malignancies, including CRC.\textsuperscript{16-18} Region 13q12.3 is the location of *HMGB1*, another gene recently surmised to influence CRC pathogenesis.\textsuperscript{19} This region lies adjacent to the coding region of *CDX2*, which has been described as a lineage-survival oncogene when amplified.\textsuperscript{20} Chromosomal amplifications in 8q and 13q have been implicated in the adenoma to carcinoma sequence of CRC for the past several decades using hybridization techniques.\textsuperscript{21-24} Copy number losses in 8p have also been previously reported in prior array hybridization and sequencing-based studies of CRC.\textsuperscript{22,24,25} Gains in 8q and losses in 8p have also both been shown to be associated with lymph node positive disease and metastasis.\textsuperscript{26-29} Additional common copy number alterations seen in CRC such as gains in 20q and losses in 18q were observed in a proportion of patients, but they did not reach the threshold for statistically significant enrichment in this small cohort.\textsuperscript{27,30}

We were able to identify several challenges that will need to be addressed to ensure the success of future efforts to analyze of cancer genomes in native South Asian populations. One notable challenge was the extent of degradation of nucleic acids in FFPE tissue, particularly for samples
stored for longer periods. We and others have described whole genome and whole exome sequencing from FFPE DNA samples in the past. In addition, several commercial service providers routinely profile tumor DNA from FFPE blocks to identify actionable cancer mutations, and most centers in the United States have switched to nucleic acid-friendly fixation protocols. In the current study, 13 samples initially identified from the pathology archives were deemed ineligible for analysis because the DNA was too degraded or not amplifiable, and sequencing libraries could not be prepared. This experience demonstrates a need to evaluate and improve fixation protocols in LMICs to ensure readiness for future genomic analyses. While DNA fragmentation in FFPE affected overall sample size of this study, the choice of shallow WGS as the analytical assay helped overcome some of these limitations, as it can be performed with limited amounts of input (in contrast to targeted sequencing). However, shallow WGS limited our ability to perform deeper characterization of single nucleotide variants in CRC driver genes such as APC, KRAS, TP53, or PIK3CA. This pilot study also does not have adequate power to find other known variants or discover additional drivers that may be unique to this population. Nevertheless, the approach outlined in the study provides the advantage of providing sufficient data for copy number alteration analysis with minimal DNA input and fewer than 30 million reads per sample.

Further investments are needed to address not only the lack of ethnic and geographic diversity of genomic atlases, but also to make precision medicine breakthroughs more accessible to LMICs. Since 2021, a multi-institutional effort in India known as the Indian Cancer Genome Atlas (ICGA) aims to build a cancer genomic database in the style of TCGA. Leaders of this initiative acknowledge the need for transnational collaboration with neighboring states in order to build a genomic network that is mutually beneficial for the entire subcontinent. Beyond regional working groups, global health partnerships between high-income countries (HICs) and LMICs can address local needs while mobilizing genomics infrastructure and personnel expertise in HICs. The resulting HIC-LMIC relationship promotes the development of local capacity and skill sets that improve global health equity. This study highlights the feasibility of such a collaboration that navigates long-distance sample shipping and coordination, material transfer agreements, and coordinated data acquisition.
In conclusion, this study demonstrates a successful HIC-LMIC collaboration that can expand our understanding of cancer genomics in South Asia. We highlight the utility of fast, reliable, and affordable shallow WGS for this purpose, which requires only a small amount of tumor DNA. In ongoing studies, we are expanding this global, interinstitutional collaboration to include prospectively collected tumor and blood samples. Our goal is that these studies can be harnessed to bridge the knowledge gap in cancer genomics, to build local capacity and technical skill, and to help expand the benefit of precision cancer medicine to patients in LMICs.
### Tables

#### Table 1: Patient and tumor characteristics (n = 30).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>19 (63.3)</td>
</tr>
<tr>
<td>Female</td>
<td>11 (36.7)</td>
</tr>
<tr>
<td><strong>Mean Age, years (SD)</strong></td>
<td>50.1 (17.8)*</td>
</tr>
<tr>
<td><strong>Tumor Location, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Colon</td>
<td>16 (53.3)</td>
</tr>
<tr>
<td>Rectosigmoid Junction</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>Rectum</td>
<td>8 (26.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td><strong>Tumor Differentiation, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>Moderate</td>
<td>14 (46.7)</td>
</tr>
<tr>
<td>Poor</td>
<td>8 (26.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td><strong>Tumor Stage, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Tis</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>T1</td>
<td>1 (3.3)</td>
</tr>
<tr>
<td>T2</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>T3</td>
<td>14 (46.7)</td>
</tr>
<tr>
<td>T4</td>
<td>7 (23.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>3 (10.0)</td>
</tr>
<tr>
<td><strong>Mean Tumor Size, cm (SD)</strong></td>
<td>6.1 (4.3)*</td>
</tr>
<tr>
<td><strong>Nodal Stage, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>16 (53.3)</td>
</tr>
<tr>
<td>N1</td>
<td>6 (20.0)</td>
</tr>
<tr>
<td>N2</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>3 (10.0)</td>
</tr>
</tbody>
</table>

Abbreviations: SD, standard deviation; cm, centimeters.

*Age at diagnosis not available for 2 patients.

†Tumor size not available for 4 patients.

Note: Percentages may not add up to 100 due to rounding.
Figures

**Figure 1:** (A) Representative ichorCNA plots showing genome-wide copy number alterations in each 500 kb window. (B) Genome-wide copy number alteration profiles for samples with tumor cellularity ≥ 3% as estimated by ichorCNA (n = 25).
Figure 2: (A) Proportional copy-number gains and losses by chromosome across samples with tumor cellularity ≥ 3%. (B) Focal amplifications (top panel) and deletions (bottom panel) across samples with tumor cellularity ≥ 3%. The y-axis represents the GISTIC2.0 \( q \)-value for each locus. The horizontal green line represents the significance threshold (\( q \)-value of 0.25).\textsuperscript{12}
References


2. GLOBOCAN. Cancer Today. GLOBOCAN. [https://gco.iarc.fr/](https://gco.iarc.fr/)


12. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number


